Company
Aldeyra Therapeutics
NASDAQ:ALDX
Aldeyra Therapeutics, Inc. (Aldeyra), formerly Aldexa Therapeutics, Inc, is a biotechnology company. The Company is focused on the development of products to treat immune-mediated, inflammatory, orphan, and other diseases that are related to free aldehydes, a naturally occurring toxic chemical species.
6 stories
Aldeyra Therapeutics shares shoot up after biotech unveils promising Phase 3 trial results for conjunctivitis treatment
The latest trial for its flagship drug reproxalap met its primary and secondary endpoints
Aldeyra Therapeutics shares pop on positive trial results for dry eye disease drug
Aldeyra now plans to introduce a Phase 3 program for dry eye disease next year
Aldeyra Therapeutics reports positive results from a phase 2a trial of its treatment for dry eye disease
In a statement, the Nasdaq-listed company said that based on statistically and clinically significant activity across a number of sign and symptom endpoints and tolerability, the ADX-102 treatment was nominated for advancement